DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)
CNY 16.16
(0.56%)
CNY 16.16
(0.56%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.17 Billion | 3.75 Billion | 1.55 Billion | 1.95 Billion | 1.7 Billion | 873.63 Million |
| Net Income | 1.16 Billion | 1.07 Billion | 804.39 Million | 1.08 Billion | 696.54 Million | 525.68 Million |
| Depreciation & Amortization | 1.69 Billion | 1.28 Billion | 1.14 Billion | 170.77 Million | 142.65 Million | 117.07 Million |
| Deferred income taxes | -23.7 Million | -27.99 Million | -49.74 Million | -2.59 Million | -14.67 Million | -6.38 Million |
| Stock-based compensation | 19.03 Million | 40.29 Million | 65.63 Million | 14.44 Million | 9.63 Million | 9.69 Million |
| Change in working capital | -60.78 Million | 828.44 Million | -878.47 Million | 495.24 Million | 596.12 Million | 219.84 Million |
| Other non-cash items | 3.87 Billion | 548.44 Million | 464 Million | 193.02 Million | 277.49 Million | 11.03 Million |
| Investing Cash Flow | -1.98 Billion | -1.29 Billion | -967.69 Million | -1.07 Billion | -1.65 Billion | -317.39 Million |
| Investments in PPE | -1.79 Billion | -1.03 Billion | -1.29 Billion | -792.32 Million | -501.4 Million | -554.39 Million |
| Acquisitions | -168.39 Million | -305.24 Million | -529.82 Million | -289.75 Million | -359.53 Million | -312.31 Million |
| Investment purchases | -104.01 Million | -428.86 Million | -1.63 Billion | -2.42 Billion | -2.46 Billion | -1.96 Billion |
| Sales/Maturities of investments | 101.85 Million | 451.64 Million | 2.47 Billion | 2.42 Billion | 1.66 Billion | 2.5 Billion |
| Other Investing Activities | -19.63 Million | 23.3 Million | 23.96 Million | 9.35 Million | 8.72 Million | 8.13 Million |
| Financing Cash Flow | -1.96 Billion | -933.56 Million | -1.61 Billion | 1.2 Billion | 420.18 Million | -436.65 Million |
| Debt repayment | -130.48 Million | -408.81 Million | -222.94 Million | -118.79 Million | -381.38 Million | -853.55 Million |
| Dividends payments | -569.45 Million | -395.46 Million | -526.89 Million | -328.17 Million | -240 Million | -262.73 Million |
| Common Stock Repurchased | -945.91 Thousand | -110.45 Thousand | -435.9 Thousand | - | - | - |
| Common Stock Issuance | - | 110.45 Thousand | 13.25 Million | - | - | - |
| Other Financing Activities | -116.17 Million | -104.46 Million | -867.56 Million | 1.66 Billion | 1.05 Billion | 679.63 Million |
| Accounts receivables | -364.73 Million | -953.43 Million | -317.98 Million | -75.04 Million | 68.52 Million | -120 Million |
| Accounts payables | 389.06 Million | 1.96 Billion | 235.17 Million | 1.11 Billion | 689.18 Million | 485.61 Million |
| Inventory | -104.16 Million | -157.39 Million | -745.92 Million | -539.6 Million | -65.84 Million | -140.97 Million |
| Other working capital | 19.03 Million | -27.99 Million | -49.74 Million | -2.59 Million | -95.72 Million | 360.82 Million |
| Cash at beginning of period | 4.49 Billion | 2.24 Billion | 3.27 Billion | 1.18 Billion | 710.8 Million | 591.22 Million |
| Cash at end of period | 4.41 Billion | 3.77 Billion | 2.24 Billion | 3.27 Billion | 1.18 Billion | 710.8 Million |
| Capital Expenditure | -1.79 Billion | -1.03 Billion | -1.29 Billion | -792.32 Million | -501.4 Million | -554.39 Million |
| Effect of forex changes on cash | - | -0.05 | - | 0.65 | - | 0.76 |
| Net cash flow / Change in cash | -76.7 Million | 1.52 Billion | -1.02 Billion | 2.09 Billion | 469.3 Million | 119.58 Million |
| Free Cash Flow | 1.38 Billion | 2.72 Billion | 260.04 Million | 1.16 Billion | 1.2 Billion | 319.24 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 200.52 Million | 259.14 Million | 398.45 Million | -7.86 Million | 1.16 Billion | 256.93 Million |
| Depreciation & Amortization | - | 456.52 Million | 456.52 Million | 453.06 Million | 1.69 Billion | -667.5 Million |
| Deferred income taxes | - | - | - | - | -23.7 Million | 592.36 Million |
| Stock-based compensation | - | - | - | 19.03 Million | 19.03 Million | -9.99 Million |
| Change in working capital | - | -28.93 Million | - | -449.85 Million | -60.78 Million | 85.14 Million |
| Other non-cash items | 541.63 Million | 738.28 Million | 828.03 Million | 1.15 Billion | 3.87 Billion | 746.89 Million |
| Investing Cash Flow | -540.43 Million | -853.05 Million | -459.37 Million | -478.07 Million | -1.98 Billion | -317.58 Million |
| Investments in PPE | -173.67 Million | -951.91 Million | -305.15 Million | -283.38 Million | -1.79 Billion | -288.69 Million |
| Acquisitions | -369.26 Million | 75.66 Million | -152.91 Million | -124.84 Million | -168.39 Million | -21.54 Million |
| Investment purchases | - | - | -2.31 Million | -46.84 Million | -104.01 Million | - |
| Sales/Maturities of investments | - | 21.19 Million | - | -16.85 Million | 101.85 Million | - |
| Other Investing Activities | 2.49 Million | 2 Million | 1 Million | -6.14 Million | -19.63 Million | -7.33 Million |
| Financing Cash Flow | 117.22 Million | -403.24 Million | -216.45 Million | -225.36 Million | -1.96 Billion | -351.7 Million |
| Debt repayment | -381.65 Million | -402.06 Million | -151.7 Million | -292.42 Million | -130.48 Million | -156.59 Million |
| Dividends payments | - | -371.48 Million | -4.02 Million | -569.45 Million | -569.45 Million | -22.4 Million |
| Common Stock Repurchased | 41.17 Million | -41.17 Million | - | -945.91 Thousand | -945.91 Thousand | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -305.59 Million | -7.35 Million | -368.15 Million | 1.46 Billion | -116.17 Million | -172.7 Million |
| Accounts receivables | - | 69.99 Million | - | -364.73 Million | -364.73 Million | -176.47 Million |
| Accounts payables | - | - | - | - | 389.06 Million | 9.99 Million |
| Inventory | - | -103.35 Million | - | -104.16 Million | -104.16 Million | 261.61 Million |
| Other working capital | - | 4.42 Million | - | 19.03 Million | 19.03 Million | -9.99 Million |
| Cash at beginning of period | 5.04 Billion | 5.36 Billion | 4.41 Billion | 3.69 Billion | 4.49 Billion | 2.67 Billion |
| Cash at end of period | 5.7 Billion | 5.04 Billion | 5.36 Billion | 4.41 Billion | 4.41 Billion | 3 Billion |
| Capital Expenditure | -173.67 Million | -951.91 Million | -305.15 Million | -283.38 Million | -1.79 Billion | -288.69 Million |
| Effect of forex changes on cash | - | - | - | - | - | -0.17 |
| Net cash flow / Change in cash | 661.58 Million | -314.23 Million | 944.56 Million | 722.21 Million | -76.7 Million | 334.54 Million |
| Free Cash Flow | 568.49 Million | -411.02 Million | 921.33 Million | 411.77 Million | 1.38 Billion | 715.13 Million |
KRYPY
PSBQ
IRB
0IL6
002031
2761